2021. Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints. SKIN The Journal of Cutaneous Medicine. 5, 5 (Sep. 2021), 524–529. DOI:https://doi.org/10.25251/skin.5.5.10.